{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00273624",
      "orgStudyIdInfo": {
        "id": "Olanzapine Augmentation"
      },
      "organization": {
        "fullName": "University Hospital Freiburg",
        "class": "OTHER"
      },
      "briefTitle": "Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial",
      "officialTitle": "Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-08",
      "overallStatus": "WITHDRAWN",
      "whyStopped": "Study withdrawn before inclusion of first participant for administrative reasons",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2005-06"
      },
      "primaryCompletionDateStruct": {
        "date": "2009-12",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2009-12",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2006-01-04",
      "studyFirstSubmitQcDate": "2006-01-04",
      "studyFirstPostDateStruct": {
        "date": "2006-01-09",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2022-08-08",
      "lastUpdatePostDateStruct": {
        "date": "2022-08-10",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Claus Normann",
        "investigatorTitle": "Prof. Dr.",
        "investigatorAffiliation": "University Hospital Freiburg"
      },
      "leadSponsor": {
        "name": "University Hospital Freiburg",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "60 patients with major depression will be treated with 10 mg Olanzapine or Placebo for 2 weeks. In case of response (reduction of depressive symptoms)the study will be continued for further 60 days.",
      "detailedDescription": "The study is using a randomized double-blind, parallel-group, placebo-controlled design. 30 patients per treatment group will be included into the study and randomized to the treatment groups using a computer program. Psychotic features of depression will be excluded by a score of 2 or less in the PANSS subscales P1, P3 and P6. Treatment resistance as defined by history of non-response to two antidepressants from different classes at an acceptable dose and period is confirmed retrospectively. If possible, treatment compliance should be confirmed by plasma level examination. After informed consent, visit 1 is performed on day 0 (inclusion criteria, history, demographics, physical examination, vital signs, HAMD, MADRS, CGI, lab). Study medication is started on day 1, the antidepressive therapy is continued at stable dose until the end of the study. Patients will receive a double-blind therapy of either 10 mg/d olanzapine or placebo. Study visits will be performed on days 4, 7, and 14 (visits 2-4: vital signs, HAMD, MADRS, CGI, lab).\n\nAfter 14 days, the patients will be classified as responders or non-responders. A responder is defined by a reduction of the initial HAM-D score of more than 50%. Study treatment will be stopped in non-responders and continued in a double-blind manner in responders for further 60 days. Thereafter, the the study medication is stopped and the patients are observed for further 14 days. Study visits will be performed every 14 days. This extension phase was added to examine if a prolonged treatment with olanzapine could ensure a sustained treatment effect. It should be excluded that olanzapine has a short-term tranquillizer-like effect or leads to unfavourable medium- to-long-term depressiogenic effects as observed with other neuroleptics used in depression ( e.g. fluspirilene). Moreover, withdrawal effects should be excluded."
    },
    "conditionsModule": {
      "conditions": [
        "Therapy-resistant Depression"
      ],
      "keywords": [
        "Therapy-resistant depression",
        "add-on therapy depression"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 0,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "olanzapine",
          "type": "EXPERIMENTAL",
          "description": "10 mg Olanzapine",
          "interventionNames": [
            "Drug: Olanzapine"
          ]
        },
        {
          "label": "placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Placebo",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Olanzapine",
          "description": "10 mg Olanzapin concurrent to antidepressive medication",
          "armGroupLabels": [
            "olanzapine"
          ],
          "otherNames": [
            "Zyprexa"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "placebo",
          "armGroupLabels": [
            "placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Hamilton-Depression-Scale- HAM-D",
          "timeFrame": "14 days"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "rate of remission (HAM-D less or equal 7)",
          "timeFrame": "14 days"
        },
        {
          "measure": "differences in HAM-D total scores",
          "timeFrame": "14 days"
        },
        {
          "measure": "differences in MADRS (Montgomery Asberg Depression Rating Scale)and CGI (Clinical Global Impression)scores",
          "timeFrame": "14 days"
        },
        {
          "measure": "predictive value of HAM-D subscales for treatment response use of comedication",
          "timeFrame": "14 days"
        },
        {
          "measure": "survival in study",
          "timeFrame": "14 days"
        },
        {
          "measure": "differences in rates of adverse events, weight",
          "timeFrame": "14 days"
        },
        {
          "measure": "differences in HAM-D scores and survival in extension phase",
          "timeFrame": "2 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* major depression without psychotic features\n* therapy resistance (2 courses of antidepressants from different classes for more than 3 weeks in adequate dose\n* HAM-D score greater/equal than 17\n* age 18-65\n\nExclusion Criteria:\n\n* bipolar disorder\n* active alcohol or illicit drug use\n* female with ineffective contraception\n* severe medical conditions, epilepsy\n* psychotic features",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Claus Normann, MD",
          "affiliation": "Department of Psychiatry, University of Freiburg",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Dept. of Psychiatry, University of Freiburg",
          "city": "Freiburg",
          "zip": "79104",
          "country": "Germany",
          "geoPoint": {
            "lat": 47.9959,
            "lon": 7.85222
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-03-13"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003863",
          "term": "Depression"
        },
        {
          "id": "D003866",
          "term": "Depressive Disorder"
        },
        {
          "id": "D061218",
          "term": "Depressive Disorder, Treatment-Resistant"
        }
      ],
      "ancestors": [
        {
          "id": "D001526",
          "term": "Behavioral Symptoms"
        },
        {
          "id": "D019964",
          "term": "Mood Disorders"
        },
        {
          "id": "D001523",
          "term": "Mental Disorders"
        }
      ],
      "browseLeaves": [
        {
          "id": "M7058",
          "name": "Depression",
          "asFound": "Depression",
          "relevance": "HIGH"
        },
        {
          "id": "M7061",
          "name": "Depressive Disorder",
          "asFound": "Depression",
          "relevance": "HIGH"
        },
        {
          "id": "M29783",
          "name": "Depressive Disorder, Treatment-Resistant",
          "asFound": "Therapy-resistant Depression",
          "relevance": "HIGH"
        },
        {
          "id": "M4818",
          "name": "Behavioral Symptoms",
          "relevance": "LOW"
        },
        {
          "id": "M21835",
          "name": "Mood Disorders",
          "relevance": "LOW"
        },
        {
          "id": "M4815",
          "name": "Mental Disorders",
          "relevance": "LOW"
        },
        {
          "id": "M14473",
          "name": "Psychotic Disorders",
          "relevance": "LOW"
        }
      ],
      "browseBranches": [
        {
          "abbrev": "BXM",
          "name": "Behaviors and Mental Disorders"
        },
        {
          "abbrev": "All",
          "name": "All Conditions"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000077152",
          "term": "Olanzapine"
        }
      ],
      "ancestors": [
        {
          "id": "D000932",
          "term": "Antiemetics"
        },
        {
          "id": "D001337",
          "term": "Autonomic Agents"
        },
        {
          "id": "D018373",
          "term": "Peripheral Nervous System Agents"
        },
        {
          "id": "D045505",
          "term": "Physiological Effects of Drugs"
        },
        {
          "id": "D005765",
          "term": "Gastrointestinal Agents"
        },
        {
          "id": "D014150",
          "term": "Antipsychotic Agents"
        },
        {
          "id": "D014149",
          "term": "Tranquilizing Agents"
        },
        {
          "id": "D002492",
          "term": "Central Nervous System Depressants"
        },
        {
          "id": "D011619",
          "term": "Psychotropic Drugs"
        },
        {
          "id": "D017367",
          "term": "Selective Serotonin Reuptake Inhibitors"
        },
        {
          "id": "D014179",
          "term": "Neurotransmitter Uptake Inhibitors"
        },
        {
          "id": "D049990",
          "term": "Membrane Transport Modulators"
        },
        {
          "id": "D045504",
          "term": "Molecular Mechanisms of Pharmacological Action"
        },
        {
          "id": "D018377",
          "term": "Neurotransmitter Agents"
        },
        {
          "id": "D018490",
          "term": "Serotonin Agents"
        }
      ],
      "browseLeaves": [
        {
          "id": "M1675",
          "name": "Olanzapine",
          "asFound": "B-cell",
          "relevance": "HIGH"
        },
        {
          "id": "M4247",
          "name": "Antidepressive Agents",
          "relevance": "LOW"
        },
        {
          "id": "M4251",
          "name": "Antiemetics",
          "relevance": "LOW"
        },
        {
          "id": "M8881",
          "name": "Gastrointestinal Agents",
          "relevance": "LOW"
        },
        {
          "id": "M16904",
          "name": "Antipsychotic Agents",
          "relevance": "LOW"
        },
        {
          "id": "M14474",
          "name": "Psychotropic Drugs",
          "relevance": "LOW"
        },
        {
          "id": "M15512",
          "name": "Serotonin",
          "relevance": "LOW"
        },
        {
          "id": "M19649",
          "name": "Selective Serotonin Reuptake Inhibitors",
          "relevance": "LOW"
        },
        {
          "id": "M20504",
          "name": "Neurotransmitter Agents",
          "relevance": "LOW"
        }
      ],
      "browseBranches": [
        {
          "abbrev": "AnEm",
          "name": "Antiemetics"
        },
        {
          "abbrev": "CNSDep",
          "name": "Central Nervous System Depressants"
        },
        {
          "abbrev": "PsychDr",
          "name": "Psychotropic Drugs"
        },
        {
          "abbrev": "Gast",
          "name": "Gastrointestinal Agents"
        },
        {
          "abbrev": "All",
          "name": "All Drugs and Chemicals"
        }
      ]
    }
  },
  "hasResults": false
}